STAT+: Pharmalittle: Pharma hunts for a cure for long Covid; Texas AG deepens puberty-blocker probe into AbbVie and Endo
And so, another working week will soon draw to a close. Not a moment too…
Category: STAT+
STAT+: Humility over hype: An AI leader at Google lays out a vision to transform medical care
From a high perch within Google, Greg Corrado is steering the development of artificial intelligence…
STAT+: Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
Even as prices rose substantially in the U.S. over a recent 12-year period, a new…
STAT+: A hospital lobbying juggernaut makes an unlikely pivot into venture capital
The American Hospital Association is a lobbying powerhouse, championing the interests of its thousands of…
STAT+: As Google looks to get struggling health efforts back on track, it turns to a safe bet with search tools
At Google, it doesn’t get much more fundamental than Search. What better place for the…
STAT+: Pharmalittle: FDA rejects Lilly drug studied only in China; AstraZeneca suffers a setback with a key cancer drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Scientists test tetanus bacteria as a weapon to target pancreatic tumors
Pancreatic cancer has proved one of the most deadly forms of the disease, and the…
STAT+: Pharmalittle: Moderna asks FDA to OK Covid shot for kids under 6; big generic maker to close U.S. plant
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: TeamHealth hit with another lawsuit for alleged overbilling, this time from an employer
A Louisiana employer filed a class-action lawsuit against TeamHealth, alleging the private-equity-backed physician staffing firm…
STAT+: Aurobindo, major generic drug maker, will close a key U.S. production plant
Aurobindo Pharma, which is based in India and is one of the largest global producers…
STAT+: Pharmalittle: FDA faces immense pressure over an ALS drug; former Biogen R&D chief seeks a reset at another biotech
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics
Al Sandrock, the top scientist at Biogen who exited last year in a dispute over…
STAT+: Pfizer inks deal with UNICEF to supply Covid pill to poor countries, but advocates say it isn’t enough
As part of an effort to widen access to its Covid-19 pill, Pfizer has reached…
STAT+: The biggest PBMs are handling more and more of the country’s drug price negotiations
Alex Schmelzer didn’t think he’d be the most-hated person in drug pricing negotiations, but he…
STAT+: An ALS therapy sets up a crucial test of the FDA’s independence
WASHINGTON — A high-profile, experimental therapy for ALS is teeing up a crucial test of…
STAT+: ‘Harmful and wasteful’: Many pediatric clinical trials end early or don’t report results
An extensive analysis of thousands of pediatric trials found one in 10 ended early —…
STAT+: Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis
Just as a trial was getting underway, AbbVie and Teva Pharmaceutical reached a settlement worth…
STAT+: What makes a biotech a biotech?
The prototypical biotech company is easy to envision: think Moderna, Alnylam, and Genentech. But what…
STAT+: Pharmalittle: Covid-19 vaccine market is getting crowded as demand wanes; Russia looks to India to supply pharmaceuticals
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: 5 tech strategies health systems are testing to combat clinician burnout
Health care workers are experiencing unprecedented levels of burnout during the pandemic, leading many to quit…
STAT+: When should drugmakers go all in and cut off essential medicines to Russia?
Just say nyet? As the war in Ukraine intensifies, several of the world’s largest pharmaceutical…
STAT+: Pharmalittle: Lawmakers face off over FDA’s accelerated approval; ivermectin failed to reduce Covid-19 hospital admissions
And so, another working week will soon draw to a close. This is, as you…
STAT+: After a dry spell for cancer immunotherapy, a new target offers a beacon of hope
Oncologists may soon have a new immuno-oncology target in their arsenal. Experts expect the Food…
STAT+: New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
More than three years after the now-infamous Chinese scientist He Jiankui sent shockwaves around the…
STAT+: Illumina sues Guardant Health, saying former employees stole trade secrets to launch liquid biopsy firm
DNA sequencing giant Illumina is suing Guardant Health, a firm that has become both its…
STAT+: Lawmakers face off about the future of the FDA’s accelerated approval pathway
WASHINGTON – Lawmakers are facing off over the future of the Food and Drug Administration’s…
STAT+: Alnylam sues Pfizer and Moderna for patent infringement in development of Covid-19 vaccines
Alnylam Pharmaceuticals has filed separate lawsuits alleging that Pfizer and Moderna infringed its patents in…
STAT+: Pharmalittle: Biogen Alzheimer’s data is published in little-known journal; WHO may reject Medicago Covid shot over ties to Philip Morris
Good morning, everyone, and how are you today? A spot of rain is descending on…
.jpg)
STAT+: A battle is brewing between a senator and a nonprofit over pharma patenting practices
As the pharmaceutical industry faces pointed criticism over its patent practices, an effort appears to…
STAT+: Biogen publishes data on its Alzheimer’s drug in a little-known journal
When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped…
STAT+: Pharmalittle: Compromise reached on Covid-19 vaccine patent waivers; Biogen reports upbeat data on its Alzheimer’s drug
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Lawmakers accuse PhRMA of providing ‘misleading information’ about drug price hikes
A group of Congressional lawmakers is accusing the pharmaceutical industry’s leading trade group of providing…
STAT+: Biden’s agency to ‘end cancer as we know it’ is finally real. But it has a chaotic road ahead
WASHINGTON — Congress has finally funded the agency that President Biden has pledged will help…
STAT+: A compromise is reached on an intellectual property waiver for Covid-19 vaccines, but does it go far enough?
After 18 months of talks, a compromise was reached on a proposal to waive intellectual…
STAT+: Gilead faces criticism for donations to state senators who backed ‘Don’t Say Gay’ bill in Florida
There was a curious dichotomy underlying the outcry over the so-called ‘Don’t Say Gay’ bill…
STAT+: Pharmalittle: Congress wants opioid-settlement tax breaks probed; another yawner of a drug-pricing hearing?
Hello, everyone, and how are you today? A shiny sun is warming the Pharmalot campus,…
Google, eyeing a broader market for medical software, strikes a deal with major health records player
Google has struck a deal to embed its clinical software tools into a patient record-keeping…
STAT+: Patients are flocking back to hospitals, but volumes are at the mercy of Covid surges, new documents show
Hospitals and outpatient clinics filled up with patients early last year, as vaccines and the…
STAT+: Three years after the Senate grilled drug makers … nothing’s changed
WASHINGTON – Back in 2019, when the Senate Finance Committee called seven drug industry executives…
STAT+: Arrowhead shareholders urged not to approve ‘excessive’ compensation for non-executive directors
In an unusual move, a prominent shareholder advisory firm is urging investors in Arrowhead Pharmaceuticals…
STAT+: Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing
SAN DIEGO — After quietly raising hundreds of millions of dollars and building a team…
.jpg)
STAT+: Watcdog says Lilly made ‘false assertions’ about impact of pausing political donations after Jan. 6 attack
Early last year, Eli Lilly (LLY) temporarily halted contributions made to members of Congress who…
STAT+: Pharmalittle: Patient groups pressure Medicare over Alzheimer’s drug; pharma says it’s duty-bound to sell meds in Russia
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Combination treatment from Nektar and Bristol Myers Squibb fails to benefit patients with melanoma, study shows
Nektar Therapeutics said Monday that its experimental immunotherapy failed to provide additional benefit for patients…
STAT+: What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting
Amylyx Pharmaceuticals is one heck of an encore. On March 30, the Food and Drug…
STAT+: Cutting-edge gene therapies could be coming for sickle cell. Will Medicaid patients be able to access them?
Gary Puckrein sees a dilemma coming that has him excited, and at the same time,…
STAT+: In New York appearance, CMS administrator pushes for Congress to act on drug prices
NEW YORK — When Chiquita Brooks-LaSure, the Biden official who oversees the Medicare and Medicaid health…
STAT+: Pharmalittle: Opioid victims and their families berate Sacklers in court hearing; Glaxo shingles vaccine campaign in U.K. is criticized
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Bankruptcy court judge OKs Purdue settlement; U.S. Senate revives legislation to curb insulin costs
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Dozens of towns and counties object to ‘hush money’ tied to Purdue opioid settlement
Ahead of a bankruptcy court hearing to approve a $6 billion settlement with Purdue Pharma…